{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T16:10:05Z","timestamp":1756311005453,"version":"3.44.0"},"reference-count":15,"publisher":"BMJ","issue":"5","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2021,5,5]]},"published-print":{"date-parts":[[2021,5]]},"abstract":"<jats:p>Terbinafine is often considered contraindicated in those with liver disease, as one of the known side effects is hepatotoxicity. We report the first case documenting the safe use of oral terbinafine in a 77-year-old woman with stable autoimmune hepatitis presenting with extensive tinea corporis. Precautions were carried out to minimise the risk of worsening hepatotoxicity, including consultation with the patient\u2019s hepatologist, limiting terbinafine exposure to less than 6 weeks, monitoring of liver function tests, and patient education. The patient\u2019s fungal infection cleared without any signs or symptoms of worsening liver disease. The rash had not recurred 6\u2009months after treatment. When terbinafine must be used in a patient with pre-existing liver disease, we recommend considering a short course of oral terbinafine after consultation with their hepatologist, obtaining baseline liver function tests with consideration of further monitoring during treatment course, and patient education on the signs and symptoms of liver injury.<\/jats:p>","DOI":"10.1136\/bcr-2021-243143","type":"journal-article","created":{"date-parts":[[2021,5,25]],"date-time":"2021-05-25T12:32:50Z","timestamp":1621945970000},"page":"e243143","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Terbinafine used safely in autoimmune hepatitis for treatment of tinea corporis"],"prefix":"10.1136","volume":"14","author":[{"given":"Jessica Elizabeth","family":"Ferguson","sequence":"first","affiliation":[{"name":"University of Kansas Medical Center, Kansas City, Kansas, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Megan","family":"Prouty","sequence":"additional","affiliation":[{"name":"Division of Dermatology, The University of Kansas Health System, Kansas City, Kansas, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2021,5,25]]},"reference":[{"doi-asserted-by":"publisher","key":"2025082708545598000_14.5.e243143.1","DOI":"10.1042\/bj2300765"},{"unstructured":"Lexicomp . Terbinafine (systemic): drug information, 2021. Available: https:\/\/www.uptodate.com\/contents\/terbinafine-systemic-drug-information?search=terbinafine&source=panel_search_result&selectedTitle=1~38&usage_type=panel&display_rank=1#F9566188","key":"2025082708545598000_14.5.e243143.2"},{"doi-asserted-by":"publisher","key":"2025082708545598000_14.5.e243143.3","DOI":"10.1046\/j.1365-2230.1998.00321.x"},{"key":"2025082708545598000_14.5.e243143.4","doi-asserted-by":"crossref","first-page":"77","DOI":"10.4103\/2229-5178.178099","article-title":"Management of tinea corporis, Tinea cruris, and tinea pedis: a comprehensive review","volume":"7","author":"Sahoo","year":"2016","journal-title":"Indian Dermatol Online J"},{"doi-asserted-by":"publisher","key":"2025082708545598000_14.5.e243143.5","DOI":"10.1001\/archderm.1989.01670230079013"},{"unstructured":"Epocrates . Epocrates Rx Drugs (Version 21.4) [Mobile application software], 2014.","key":"2025082708545598000_14.5.e243143.6"},{"doi-asserted-by":"publisher","key":"2025082708545598000_14.5.e243143.7","DOI":"10.1007\/s11096-014-9969-y"},{"key":"2025082708545598000_14.5.e243143.8","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.jaad.2020.09.004","article-title":"Retrospective analysis of laboratory abnormalities in patients with preexisting liver and hematologic diseases prescribed terbinafine for onychomycosis","volume":"84","author":"Wang","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"2025082708545598000_14.5.e243143.9","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/liv.13535","article-title":"Acute liver failure induced by idiosyncratic reaction to drugs: challenges in diagnosis and therapy","volume":"38","author":"Tujios","year":"2018","journal-title":"Liver Int"},{"key":"2025082708545598000_14.5.e243143.10","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1053\/j.gastro.2016.12.016","article-title":"Association of Liver Injury From Specific Drugs, or Groups of\u00a0Drugs, With Polymorphisms in HLA and Other Genes in a\u00a0Genome-Wide Association Study","volume":"152","author":"Nicoletti","year":"2017","journal-title":"Gastroenterology"},{"key":"2025082708545598000_14.5.e243143.11","doi-asserted-by":"crossref","first-page":"321","DOI":"10.4103\/0970-258X.239071","article-title":"Terbinafine-induced liver injury","volume":"30","author":"Kaushal","year":"2017","journal-title":"Natl Med J India"},{"key":"2025082708545598000_14.5.e243143.12","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.gastrohep.2018.05.022","article-title":"Terbinafine-induced hepatotoxicity","volume":"42","author":"Mej\u00edas Manzano","year":"2019","journal-title":"Gastroenterol Hepatol"},{"doi-asserted-by":"publisher","key":"2025082708545598000_14.5.e243143.13","DOI":"10.1345\/aph.1H400"},{"key":"2025082708545598000_14.5.e243143.14","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1111\/bjd.15854","article-title":"Clinical presentation of terbinafine-induced severe liver injury and the value of laboratory monitoring: a critically Appraised topic","volume":"177","author":"Kramer","year":"2017","journal-title":"Br J Dermatol"},{"key":"2025082708545598000_14.5.e243143.15","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1001\/jamadermatol.2018.3578","article-title":"Utility of laboratory test result monitoring in patients taking oral terbinafine or griseofulvin for dermatophyte infections","volume":"154","author":"Stolmeier","year":"2018","journal-title":"JAMA Dermatol"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2021-243143","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T15:55:04Z","timestamp":1756310104000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2021-243143"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":15,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2021,5,25]]},"published-print":{"date-parts":[[2021,5]]}},"alternative-id":["10.1136\/bcr-2021-243143"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2021-243143","relation":{},"ISSN":["1757-790X"],"issn-type":[{"type":"electronic","value":"1757-790X"}],"subject":[],"published":{"date-parts":[[2021,5]]}}}